Androsin
Based on 1 Customer Validation
Androsin is an active compound isolated from Picrorhiza Kurroa Royle ex Benth. Androsin activates AMPKα/PI3K/Beclin1/LC3 signaling pathway, inhibits SREBP1c/FASN signaling pathway. Androsin can be used in research of asthma and non-alcoholic fatty liver disease (NAFLD). Androsin is orally active.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.94%
- CAS No.: 531-28-2
- 화학식: C15H20O8
- 분자량:328.31
-
보관:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
All AMPK Isoforms
More
Biological Activity
Androsin (0.001-0.1 mg/mL) inhibited the histamine release in human polymorphonuclear leukocytes induced by allergens (such as a-IgE)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Androsin (10 mg/kg, po, once daily for 7 weeks) induces autophagy and inhibits lipid accumulation, alleviates the symptoms of non-alcoholic fatty liver disease (NAFLD) in HFrD-fed ApoE-/- mouse models[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Guinea pigs bronchial obstruction models[1]
-
Dosage:10 mg/kg
-
Administration:po, single dose
-
Result:Prevented allergen-induced bronchial obstruction with an inhibition rate of 57%-71%.
Prevented PAF-induced bronchial obstruction with an inhibition rate of 48%.
-
Animal Model:HFrD-fed ApoE-/- mouse models[2]
-
Dosage:10 mg/kg
-
Administration:po, once daily for 7 weeks
-
Result:Decreased serum ALT, AST, and cholesterol levels.
Decreased expressions of SREBP1c, FASN, α-SMA, collagens, and TGF-β in the liver.
Increased expressions of PI3K, AMPKα, Beclin1, and LC3B.
Chemical Information
-
CAS No. 531-28-2
-
Appearance Solid
-
분자량 328.31
-
화학식 C15H20O8
-
Color White to off-white
-
SMILES
CC(C1=CC=C(O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)C(OC)=C1)=O
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
용액&용해도
DMSO : 125 mg/mL (380.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.34 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.34 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Dorsch W, et al. Antiasthmatic effects of Picrorhiza kurroa: androsin prevents allergen- and PAF-induced bronchial obstruction in guinea pigs. Int Arch Allergy Appl Immunol. 1991;95(2-3):128-33. [Content Brief]
[2]. Singh A, et al., Androsin alleviates non-alcoholic fatty liver disease by activating autophagy and attenuating de novo lipogenesis. Phytomedicine. 2024 Jul;129:155702. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0459 mL | 15.2295 mL | 30.4590 mL | 76.1475 mL |
| 5 mM | 0.6092 mL | 3.0459 mL | 6.0918 mL | 15.2295 mL | |
| 10 mM | 0.3046 mL | 1.5230 mL | 3.0459 mL | 7.6148 mL | |
| 15 mM | 0.2031 mL | 1.0153 mL | 2.0306 mL | 5.0765 mL | |
| 20 mM | 0.1523 mL | 0.7615 mL | 1.5230 mL | 3.8074 mL | |
| 25 mM | 0.1218 mL | 0.6092 mL | 1.2184 mL | 3.0459 mL | |
| 30 mM | 0.1015 mL | 0.5077 mL | 1.0153 mL | 2.5383 mL | |
| 40 mM | 0.0761 mL | 0.3807 mL | 0.7615 mL | 1.9037 mL | |
| 50 mM | 0.0609 mL | 0.3046 mL | 0.6092 mL | 1.5230 mL | |
| 60 mM | 0.0508 mL | 0.2538 mL | 0.5077 mL | 1.2691 mL | |
| 80 mM | 0.0381 mL | 0.1904 mL | 0.3807 mL | 0.9518 mL | |
| 100 mM | 0.0305 mL | 0.1523 mL | 0.3046 mL | 0.7615 mL |